Avantor (AVTR)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$14.88-2.43%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Improve operating income from recent declines: Op margin 7.2% vs target ~15.2% (implied $100M/$656M).
Avantor is improving its business with new leadership focused on cost and efficiency. It beat earnings in Q1 2026 with EPS of $0.17, above estimates. Analysts expect EPS to grow to $0.79 in 2026 and $0.85 in 2027. The stock trades at a discount to peers, reflecting potential upside if the turnaround succeeds.
Revenue has been flat at $1.58 billion and operating income fell from $147 million to $99 million in Q1 2026. The company remains unprofitable and faces leadership changes that could slow progress. Analysts expect very low revenue growth of about 1%, showing limited confidence in a strong recovery.
The market price reflects a cautious view with about 44% discount to our valuation model and low expected revenue growth near 1%. Our view differs by seeing potential for operational improvement and earnings growth if management executes well.
Breaks if: EPS falls below $0.79 in FY26 or $0.85 in FY27
Breaks if: No measurable operational improvements or worsening costs
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth. The current thesis state is intact, supported by strong recent financial performance, but management execution has been volatile.
The market currently prices AVTR as cheap compared to its peers, with a slight expectations gap. Valuation has risen recently, indicating some recognition of its performance but still reflects cautious sentiment.
Fundamentals are likely to show modest improvement in top-line growth, as management has prioritized this area. However, operating income has seen a slight decline, indicating challenges in improving profitability.
The thesis hinges on management's ability to maintain guidance and execute on growth priorities. Additionally, sector performance, particularly from leading companies, could influence AVTR's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis. However, the Revival program faces persistent margin pressure, which threatens customer experience.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Operating income falls below $100M in FY26
Enhance profitability through operational improvements and cost management.
Management stated improving operating income as a priority in 4 of last 4 quarters. Operating income was $121.8M in 2026-Q2, slightly down from $126.4M in 2025-Q4, with margins declining from 7.6% to 7.2%. Despite management's focus, operating income shows a slight decline, indicating limited progress on this priority.
“Operating income was $121.8 million with a margin of 7.2%.”
“Operating income was $99.5 million with a margin of 6.3%.”
“Operating income was $126.4 million with a margin of 7.6%.”
“CEO: 'We are moving with urgency to execute Revival and turn around the performance of this great business.'”
Breaks if: YoY revenue growth falls below 0% in FY26
Overall, AVTR's performance and management focus suggest a cautious but stable outlook for the next 1 to 3 years. Not investment advice.